{"id":"NCT03017508","sponsor":"Yale University","briefTitle":"Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder","officialTitle":"Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-01","primaryCompletion":"2019-12","completion":"2021-01-29","firstPosted":"2017-01-11","resultsPosted":"2021-05-20","lastUpdate":"2021-05-20"},"enrollment":22,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"OTHER"},"conditions":["Social Anxiety Disorder","Performance Anxiety"],"interventions":[{"type":"DRUG","name":"BHV-0223","otherNames":["sublingual riluzole"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BHV-0223 (Sublingual Riluzole)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of the current proposal is to examine if sublingual riluzole can reduce anxiety in people with social anxiety disorder during a public speaking task.","primaryOutcome":{"measure":"VAS-anxiety Immediately After the Impromptu Speech Task","timeFrame":"up to 60 minutes","effectByArm":[{"arm":"BHV-0223 (Sublingual Riluzole)","deltaMin":54.3,"sd":23.6},{"arm":"Placebo","deltaMin":62.6,"sd":13.7}],"pValues":[{"comp":"OG000 vs OG001","p":"0.056"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["15078116","16330605","18698875","17141740","12051488","9714948"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Temporary perioral numbing"]}}